Monday, 10 April 2017

Glenmark Pharma bags Approval for Fenofibrate Capsules

Glenmark Pharmaceuticals has said that its US arm has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg, the generic version of Tricor® Micronized Capsules, 67 mg, 134 mg, and 200 mg of AbbVie, Inc. 

Two days Free Trials and best services packages in for dealing in Stock market click here to get >>http://ripplesadvisory.com/stock-future-hni-.php
  One Missed call on @9644405056.

According to IMS Health sales data for the 12 month period ending February 2017, the Tricor® Micronized Capsules, 67 mg, 134 mg and 200 mg market1 achieved annual sales of approximately USD 97.5 million. 

Glenmark’s current portfolio consists of 114 products authorized for distribution in the U.S. marketplace and approximately 64 ANDA’s pending approval with the U.S. FDA. 

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. Meanwhile, shares of the company were trading at Rs 868.80 apiece, up 0.70 per cent from the previous close.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.